TPST — Tempest Therapeutics Share News
0.000.00%
Last trade - 00:00Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview
Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview
Brief: Tempest Receives Clearance To Proceed With Pivotal Trial Of Amezalpat Combination Therapy For First-Line Hcc In China
Brief: Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Tempest Therapeutics Inc expected to post a loss of $3.51 a share - Earnings Preview
Tempest Therapeutics Inc expected to post a loss of $3.29 a share - Earnings Preview
Tempest rises as company eyes potential merger to advance liver cancer drug
Brief: Tempest Therapeutics Announced 1-For-13 Reverse Stock Split
Tempest Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Tempest Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Tempest Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition
Brief: Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat
Brief: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat
Tempest Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
Tempest Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview